Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2 (original) (raw)
The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2
Pieter Pretorius
Journal of neurosurgery. Spine, 2016
View PDFchevron_right
Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients
KENSHO IWATATE
Neurologia medico-chirurgica
View PDFchevron_right
Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients
Parv Mehta
Neuro-Oncology Advances
View PDFchevron_right
Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation
Rosalie Ferner
Neuro-Oncology Practice, 2016
View PDFchevron_right
Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2
Vianney Gaillard
Journal of Neuro-Oncology, 2015
View PDFchevron_right
Bevacizumab Treatment for Vestibular Schwannoma in a Patient with Neurofibromatosis Type 2: Hearing Improvement and Tumor Shrinkage
David Rondonotti
Tumori Journal, 2015
View PDFchevron_right
The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2
Michael Slancar
Australasian Journal of Neuroscience, 2021
View PDFchevron_right
Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2
Vanessa Merker
Otology & Neurotology, 2012
View PDFchevron_right
Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas
Christian Hagel
Neuropathology, 2012
View PDFchevron_right
Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients
Vanessa Merker
PLoS ONE, 2013
View PDFchevron_right
Clinicopathologic Assay of 15 Tumor Resections in a Family with Neurofibromatosis Type 2
Gordana Juric-Sekhar
Journal of Neurological Surgery Part B: Skull Base, 2012
View PDFchevron_right
Comparing the sensitivity of linear and volumetric MRI measurements to detect changes in the size of vestibular schwannomas in patients with neurofibromatosis type 2 on bevacizumab treatment
Pieter Pretorius
The British journal of radiology, 2016
View PDFchevron_right
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas
Vanessa Merker
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016
View PDFchevron_right
Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
Timothy Padera
New England Journal of Medicine, 2009
View PDFchevron_right
Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype
Annika Wefers
Acta Neuropathologica, 2021
View PDFchevron_right
Long-term natural history of neurofibromatosis Type 2–associated intracranial tumors
John Butman
Journal of Neurosurgery, 2012
View PDFchevron_right
Current Concepts in Management of Vestibular Schwannomas in Neurofibromatosis Type 2
Rosalie Ferner
Current Otorhinolaryngology Reports, 2014
View PDFchevron_right
Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis
Soma Sengupta
International Journal of Molecular Sciences, 2021
View PDFchevron_right
Multiple primary cranio-spinal tumours in a 13-year-old female with neurofibromatosis type 2 management strategy
Ewa Bien
Child's Nervous System, 2011
View PDFchevron_right
Multicenter, prospective, phase 2 study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma
Lloyd Edwards
Neuro-oncology, 2023
View PDFchevron_right
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2
Rosalie Ferner
American Journal of Medical Genetics Part A, 2012
View PDFchevron_right
Successful step-by-step treatment of multiple tumours in neurofibromatosis type 2
Andrii Sirko
Interdisciplinary Neurosurgery, 2019
View PDFchevron_right
Role Of Bevacizumab As A Prophylactic And Rehabilitative Treatment Modality In Cases Of Sporadic And Syndromic Vestibular Schwannoma: Fifty Shades Of Grey!
Ketan Kataria
Interdisciplinary Neurosurgery, 2019
View PDFchevron_right
Multiple central nervous system tumors, neurofibromatosis type 2, a case report
çağdaş erdoğan
Pamukkale Medical Journal, 2015
View PDFchevron_right
Endoglin (CD105) expression in neurofibromatosis type 2 vestibular schwannoma
Elisabetta Zanoletti
Head & Neck, 2019
View PDFchevron_right
Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis
Ka-loh Li
Neuro-Oncology, 2015
View PDFchevron_right
Neurofibromatosis Type 2: A Pandora’s Box of Variable Presentations
ashok gandhi
Indian Journal of Neurosurgery, 2021
View PDFchevron_right
Extraordinary Tumor Growth Rates in Bilateral Meningioma-Vestibular Schwannoma Collision Tumors in a Patient with Neurofibromatosis Type 2: Case Report and Literature Review
Rocio Zamora
SN Comprehensive Clinical Medicine, 2020
View PDFchevron_right
Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort
Rosalie Ferner
Journal of Neuro-Oncology, 2016
View PDFchevron_right
Cerebral vasculopathy in childhood neurofibromatosis type 2: cause for concern?
Rosalie Ferner
Developmental Medicine & Child Neurology
View PDFchevron_right
Neurofibromatosis 2011: a report of the Children’s Tumor Foundation Annual Meeting
Ludwine Messiaen
Acta Neuropathologica, 2012
View PDFchevron_right
Antiangiogenic agents for nonmalignant brain tumors
David Gutmann
Journal of neurological surgery. Part B, Skull base, 2013
View PDFchevron_right